DE69729183T2 - Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen - Google Patents

Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen Download PDF

Info

Publication number
DE69729183T2
DE69729183T2 DE69729183T DE69729183T DE69729183T2 DE 69729183 T2 DE69729183 T2 DE 69729183T2 DE 69729183 T DE69729183 T DE 69729183T DE 69729183 T DE69729183 T DE 69729183T DE 69729183 T2 DE69729183 T2 DE 69729183T2
Authority
DE
Germany
Prior art keywords
dihydrobenzofuranes
compounds useful
related compounds
flamming
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69729183T
Other languages
English (en)
Other versions
DE69729183D1 (de
Inventor
Ichih Wu
Michael Janusz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of DE69729183D1 publication Critical patent/DE69729183D1/de
Application granted granted Critical
Publication of DE69729183T2 publication Critical patent/DE69729183T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69729183T 1996-02-01 1997-01-30 Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen Expired - Fee Related DE69729183T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/595,337 US5618835A (en) 1996-02-01 1996-02-01 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
PCT/US1997/001314 WO1997028147A1 (en) 1996-02-01 1997-01-30 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
DE69729183D1 DE69729183D1 (de) 2004-06-24
DE69729183T2 true DE69729183T2 (de) 2004-10-07

Family

ID=24382842

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69729183T Expired - Fee Related DE69729183T2 (de) 1996-02-01 1997-01-30 Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen

Country Status (15)

Country Link
US (1) US5618835A (de)
EP (1) EP0888323B1 (de)
JP (1) JP3095424B2 (de)
KR (1) KR100322402B1 (de)
CN (1) CN1125062C (de)
AT (1) ATE267187T1 (de)
AU (1) AU730262B2 (de)
BR (1) BR9707247A (de)
CA (1) CA2244203A1 (de)
DE (1) DE69729183T2 (de)
DK (1) DK0888323T3 (de)
ES (1) ES2221950T3 (de)
MX (1) MX9806250A (de)
NO (1) NO983530L (de)
WO (1) WO1997028147A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (de) * 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
CA2295055A1 (en) * 1997-06-27 1999-01-07 Kaneka Corporation Heat shock factor activity inhibitor
CA2306914A1 (en) 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Antirheumatic
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6900242B2 (en) 2001-06-13 2005-05-31 Magnachem International Laboratories, Inc. Lactone formulations and method of use
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
CN102579427A (zh) 2002-11-05 2012-07-18 马格纳化学国际实验室公司 合成的内酯制剂及其使用方法
JP2006509765A (ja) * 2002-11-22 2006-03-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
CA2741526A1 (en) 2008-10-24 2010-04-29 Magnachem International Laboratories, Inc. Method for screening for compounds selectively interacting with rad9
CN102301215B (zh) 2009-01-27 2014-03-26 国立大学法人名古屋大学 膜张力测定装置
EP2398500B1 (de) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Arzneiabgabesystem auf glutathion-basis
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019305B2 (ja) * 1976-07-02 1985-05-15 ウェルファイド株式会社 ジヒドロベンゾフラン誘導体
IT1093805B (it) * 1978-01-31 1985-07-26 Erba Carlo Spa Derivati del 2h-benzofuran-3-one e procedimento per la loro preparazione
US4470440A (en) * 1982-09-30 1984-09-11 Thor Harry A Impact producing tool
DE3777366D1 (de) * 1986-12-27 1992-04-16 Takeda Chemical Industries Ltd 2,3-dihydro-cumaron-derivate, ihre herstellung und verwendung.
US4849428A (en) * 1987-11-23 1989-07-18 The Procter & Gamble Company Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use
JP2855341B2 (ja) * 1988-06-10 1999-02-10 武田薬品工業株式会社 新規２―置換クマラン誘導体
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
FR2645537B1 (fr) * 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique
US4975457A (en) * 1989-09-25 1990-12-04 Merck & Co., Inc. Trans 2,3-disubstituted-2,3-dihydro-5-hydroxy-benzofurans as inhibitors of leukotriene biosynthesis
EP0458970A4 (en) * 1989-11-17 1992-05-13 Meiji Milk Products Company Limited Benzofuran derivative, process for preparing the same, and pharmaceutical comprising the same as active ingredient
US5091533A (en) * 1990-03-12 1992-02-25 Merck Frosst Canada, Inc. 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
JPH05505610A (ja) * 1990-03-27 1993-08-19 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ阻害剤
ES2301161T3 (es) * 1994-07-27 2008-06-16 Vanderbilt University Compuestos de dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents

Also Published As

Publication number Publication date
DE69729183D1 (de) 2004-06-24
NO983530L (no) 1998-09-30
MX9806250A (es) 1998-11-30
JP3095424B2 (ja) 2000-10-03
CA2244203A1 (en) 1997-08-07
AU730262B2 (en) 2001-03-01
CN1210530A (zh) 1999-03-10
BR9707247A (pt) 1999-07-20
NO983530D0 (no) 1998-07-31
ATE267187T1 (de) 2004-06-15
KR19990082222A (ko) 1999-11-25
CN1125062C (zh) 2003-10-22
AU1843397A (en) 1997-08-22
JPH11506121A (ja) 1999-06-02
US5618835A (en) 1997-04-08
EP0888323A1 (de) 1999-01-07
KR100322402B1 (ko) 2002-05-09
EP0888323B1 (de) 2004-05-19
WO1997028147A1 (en) 1997-08-07
ES2221950T3 (es) 2005-01-16
DK0888323T3 (da) 2004-08-09

Similar Documents

Publication Publication Date Title
DE69729183D1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK0915898T3 (da) Krystalform I af clarithromycin
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
TR200001203T2 (tr) Yeni birleşik maddeler
PT902789E (pt) Derivados de androsteno
DE69802615D1 (de) Triaromatische Verbindungen, diese enthaltende Zusammensetzungen sowie ihre Anwendungen
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
DE69814135D1 (de) 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
EA199900246A1 (ru) Фармацевтические соединения
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
DE59903759D1 (de) Ektoparasitizide mittel
GB9907571D0 (en) Compounds
ATE202084T1 (de) Schwefelenthaltende di-ter-butylphenol- verbindungen brauchbar als entzündungshemmende mittel
DE69514100D1 (de) Substituierte kondensierte und verbrückte bicyclische verbindungen als therapeutische mittel
DE60005517D1 (de) Kaliumkanal-blockierende mittel
DE69535697D1 (de) Dihydrobenzofurane und verwandte verbindungen als entzündungshemmende mittel
DE69230644D1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
AU5434899A (en) Cancer treatment
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee